



Recent Publications – Dr Mei Mei Ho

63. Fitzpatrick M, **Ho MM**, Clark S, Dagg B, Khatri B, Lanni F, Williams A, Brennan M, Laddy D, Walker B. 2019 Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies. *Tuberculosis*. **114** 47–53.
62. van Meijgaarden KE, Khatri B, Smith SG, Driittij AMHF, de Paus RA, Goeman JJ, **Ho MM**, Dockrell HM, McShane H, Joosten SA, Ottenhoff THM. 2018. Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies. *PLoS One*. **13** (9): e0201205.
61. Kaufmann SHE, Dockrell HM, Drager N, **Ho MM**, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Thole J, Verreck F, Williams A, Stenger S. 2017. TBVAC2020: Advancing TB vaccines from discovery to clinical development. *Frontiers in Immunology* **8**: 1203
60. Smith SG, Harris SA, Satti I, Bryan D, Walker KB, Dockrell HM, McShane H and **Ho MM**. 2017. Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials. *PloS One* **12** (10): e0184391.
59. Bryan D, Silva N, Rigsby P, Dougall T, Corran P, Bowyer PW, **Ho MM** and the Collaborative study group. 2017 The establishment of a WHO Reference Reagent for anti-malaria (*Plasmodium falciparum*) human serum. *Malaria J*, **16** (1):314.
58. García-Cuesta EM, Estes G, Ashiru O, López-Cobo S, Álvarez-Maestro M, Linares A, **Ho MM**, Martínez-Piñeiro L, Reyburn HT & Valés-Gómez M. 2017 Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes. *Oncolmmunology* **6** (4): e1293212.
57. Lahey T, Laddy D, Hill K, Schaeffer J, Hogg A, Keeble J, Dagg B, **Ho MM**, Arbeit RD, Fordham von Reyn C. 2016 Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. *PLoSOne* **11** (12): e0168521.
56. McDonald JU, Ekeruche-Makinde J, **Ho MM**, Tregoning JS, and Ashiru O. 2016. Development of a custom pentaplex sandwich immunoassay using Protein-G coupled beads for the Luminex(R) xMAP(R) platform. *J. Immunol. Methods* **433** 6-16.
55. Garcia-Cuesta EM, Estes G, Ashiru O, Rodríguez-Alcázar J, Alvarez-Maestro M, Lopez-Cobo S, Linares Espinos E, Reyburn H, Linares A, **Ho MM**, Martínez-Piñeiro L, Valés-Gómez M 2015 CD56 bright natural killer cells primed by innate immune cytokines dominate the immune response stimulated by BCG to non-muscle invasive bladder cancer, *European Urology Supplements* **14** (2) e30.
54. Geels MJ, Thogersen RL, Guzman CA, **Ho MM**, Verreck F, Collin N, Robertson JS, McConkey SJ, Kaufmann SH & Leroy O 2015 TRANSVAC research infrastructure - Results and lessons learned from the European network of vaccine research and development. *Vaccine* **33** 5481-5487.
53. **Ho MM**, Baca-Estrada M, Conrad C, Karikari-Boateng E & Kang HN 2015 Implementation workshop of WHO guidelines on evaluation of malaria vaccines: Current regulatory concepts and issues related to vaccine quality, Pretoria, South Africa 07 Nov 2014. *Vaccine* **33** 4359-4364.
52. Dagg B, Hockley J, Rigsby P & **Ho MM** 2014 The establishment of sub-strain specific WHO Reference Reagents for BCG vaccine. *Vaccine* **32** 6390-6395.

51. **Ho MM**, Markey K, Rigsby P, Hockley J & Corbel MJ 2011 Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains. *Vaccine* **29** 512-518.
50. Lancaster L, Saydam M, Markey K, **Ho MM** & Mawas F 2011 Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III. *Vaccine* **29** 3213-3221.
49. Lancaster LE, Markey K & **Ho MM** 2011 An assessment of thermal stability of Clostridium difficile toxoid formulations. *Hum.Vaccin.* **7** 202-210.
48. **Ho MM**, Southern J, Kang HN & Knezevic I 2010 WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22-23 September 2009. *Vaccine* **28** 6945-6950.
47. Markey K, **Ho MM**, Choudhury B, Seki M, Ju L, Castello-Branco LR, Gairola S, Zhao A, Shibayama K, Andre M & Corbel MJ 2010 Report of an international collaborative study to evaluate the suitability of multiplex PCR as an identity assay for different sub-strains of BCG vaccine. *Vaccine* **28** 6964-6969.
46. Walker KB, Brennan MJ, **Ho MM**, Eskola J, Thiry G, Sadoff J, Dobbelaer R, Grode L, Liu MA, Fruth U & Lambert PH 2010 The second Geneva Consensus: Recommendations for novel live TB vaccines. *Vaccine* **28** 2259-2270.
45. Mawas F, **Ho MM** & Corbel MJ 2009 Current progress with Moraxella catarrhalis antigens as vaccine candidates. *Expert.Rev.Vaccines.* **8** 77-90.
44. **Ho MM**, Markey K, Rigsby P, Jensen SE, Gairola S, Seki M, Castello-Branco LR, Lopez-Vidal Y, Knezevic I & Corbel MJ 2008 Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. *Vaccine* **26** 4754-4757.
43. Mawas F, **Ho MM**, Huskisson R, Saydam M & Corbel MJ 2007 Physico-chemical characterisation and immunogenicity of a multi-valent candidate vaccine against non-typeable Haemophilus influenzae and Moraxella catarrhalis. *Vaccine* **25** 4801-4808.
42. **Ho MM**, Bolgiano B, Martino A, Kairo SK & Corbel MJ 2006 Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine. *Hum.Vaccin.* **2** 89-98.
41. **Ho MM**, Kairo SK & Corbel MJ 2006 Tuberculin purified protein derivative (PPD) immunoassay as an *in vitro* alternative assay for identity and confirmation of potency. *Hum.Vaccin.* **2** 29-33.
40. Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, **Ho MM**, Mayner RE, Thole J, Walker KB, Liu M & Lambert PH 2005 New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. *Vaccine* **23** 3753-3761.
39. Fricke B, Argent AC, Chetty MC, Pizzey AR, Turner EJ, **Ho MM**, Iolascon A, von Düring M & Stewart GW 2003 The "stomatin" gene and protein in overhydrated hereditary stomatocytosis. *Blood* **102** 2268-2277.
38. Turner EJ, Jarvis HG, Chetty MC, Landon G, Rowley PS, **Ho MM** & Stewart GW 2003 ATP-dependent vesiculation in red cell membranes from different hereditary stomatocytosis variants. *Br.J.Haematol.* **120** 894-902.
37. **Ho MM**, Mawas F, Bolgiano B, Lemercinier X, Crane DT, Huskisson R & Corbel MJ 2002 Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. *Vaccine* **20** 3509-3522.
36. Jumel K, **Ho MM** & Bolgiano B 2002 Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering. *Biotechnol.Appl.Biochem.* **36** 219-226.
35. **Ho MM**, Lemercinier X, Bolgiano B, Crane D & Corbel MJ 2001 Solution stability studies of the subunit components of meningococcal C oligosaccharide-CRM197 conjugate vaccines. *Biotechnol.Appl.Biochem.* **33** 91-98.

34. **Ho MM**, Bolgiano B & Corbel MJ 2000 Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. *Vaccine* **19** 716-725.
33. **Ho MM**, Lemercinier X, Bolgiano B & Corbel MJ 2000 Monitoring stability of meningococcal group C conjugate vaccines; correlation of physico-chemical methods and immunogenicity assays. *Dev.Biol.(Basel)* **103** 139-150.
32. Coles SE, **Ho MM**, Chetty MC, Nicolaou A & Stewart GW 1999 A variant of hereditary stomatocytosis with marked pseudohyperkalaemia. *Br.J.Haematol.* **104** 275-283.
31. Coles SE, Chetty MC, **Ho MM**, Nicolaou A, Kearney JW, Wright SD & Stewart GW 1999 Two British families with variants of the 'cryohydrocytosis' form of hereditary stomatocytosis. *Br.J.Haematol.* **105** 1055-1065.
30. **Ho MM** & Vinson GP 1998 Transcription of (pro) renin mRNA in the rat adrenal cortex, and the effects of ACTH treatment and a low sodium diet. *J.Endocrinol.* **157** 217-223.
29. Vinson GP, **Ho MM** & Puddefoot JR 1998 Adrenocortical zonation and the adrenal renin-angiotensin system. *Endocr.Res.* **24** 677-686.
28. Vinson GP, Teja R, **Ho MM**, Hinson JP & Puddefoot JR 1998 The role of the tissue renin-angiotensin system in the response of the rat adrenal to exogenous angiotensin II. *J.Endocrinol.* **158** 153-159.
27. Vinson GP & **Ho MM** 1998 The adrenal renin/angiotensin system in the rat. *Horm.Metab Res.* **30** 355-359.
26. Vinson GP & **Ho MM** 1998 Origins of zonation: the adrenocortical model of tissue development and differentiation. *Clin.Exp.Pharmacol.Physiol Suppl* **25** S91-S96.
25. You Z, Gao X, **Ho MM** & Borthakur D 1998 A stomatin-like protein encoded by the slp gene of *Rhizobium etli* is required for nodulation competitiveness on the common bean. *Microbiology* **144 (Pt 9)** 2619-2627.
24. Harrison-Bernard LM, Navar LG, **Ho MM**, Vinson GP & el Dahr SS 1997 Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. *Am.J.Physiol* **273** F170-F177.
23. **Ho MM** & Vinson GP 1997 Peptide growth factors and the adrenal cortex. *Microsc.Res.Tech.* **36** 558-568.
22. **Ho MM**, Nicolaou A, Argent AC & Stewart GW 1997 Trans-bilayer phospholipid movements in human red blood cells deficient in the 32 kDa Band-7.2b membrane protein, 'stomatin'. *Biochem.Soc.Trans.* **25** 492S.
21. Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, **Ho MM**, Payne JG & Vinson GP 1997 Angiotensin II type 1 receptor expression in human breast tissues [published erratum appears in Br J Cancer 1997;76(6):827]. *Br.J.Cancer* **75** 1279-1283.
20. Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, **Ho MM**, Payne JG & Vinson GP 1997 Angiotensin II type 1 receptor expression in human breast tissues. *Br.J.Cancer* **75** 1279-1283.
19. Hinson JP, **Ho MM**, Vinson GP & Kapas S 1996 Vasoactive intestinal peptide is a local regulator of adrenocortical function. *Endocr.Res.* **22** 831-838.
18. Marsigliante S, Muscella A, Vilella S, Nicolardi G, Ingrosso L, Ciardo V, Zonno V, Vinson GP, **Ho MM** & Storelli C 1996 A monoclonal antibody to mammalian angiotensin II AT1 receptor recognizes one of the angiotensin II receptor isoforms expressed by the eel (*Anguilla anguilla*). *J.Mol.Endocrinol.* **16** 45-56.
17. Vendeira P, Pignatelli D, Neves D, Magalhaes MM, Magalhaes MC, **Ho MM** & Vinson GP 1996 New insights into zonal differentiation of adrenal autotransplants in the rat: an immunohistochemical study. *J.Endocrinol.* **149** 497-502.
16. Vilella S, Zonno V, Marsigliante S, Ingrosso L, Muscella A, **Ho MM**, Vinson GP & Storelli C 1996 Angiotensin II stimulation of the basolateral located Na⁺/H⁺ antiporter in eel (*Anguilla anguilla*) enterocytes. *J.Mol.Endocrinol.* **16** 57-62.

15. Vinson GP, Teja R, **Ho MM**, Hinson JP & Puddefoot JR 1996 Role of the tissue renin-angiotensin system in the response of the rat adrenal to exogenous angiotensin II. *Endocr.Res.* **22** 589-593.
14. **Ho MM** & Vinson GP 1995 Endocrine control of the distribution of basic fibroblast growth factor, insulin-like growth factor-I and transforming growth factor- beta 1 mRNAs in adult rat adrenals using non-radioactive in situ hybridization. *J.Endocrinol.* **144** 379-387.
13. Pignatelli D, Pinto P, Almeida H, Magalhaes MM, Magalhaes MC, **Ho MM** & Vinson GP 1995 The development of the adrenal cortex in the rat. An immunohistochemical study. *Endocr.Res.* **21** 129-136.
12. Vinson GP, Teja R, **Ho MM** & Puddefoot JR 1995 A two cell type theory for aldosterone biosynthesis: the roles of 11 beta-hydroxylase and aldosterone synthase, and a high capacity tightly binding steroid carrier for 18-hydroxydeoxycorticosterone in rat adrenals. *J.Endocrinol.* **144** 359-368.
11. Vinson GP, Puddefoot JR, **Ho MM**, Barker S, Mehta J, Saridogan E & Djahanbakhch O 1995 Type 1 angiotensin II receptors in rat and human sperm. *J.Endocrinol.* **144** 369-378.
10. Vinson GP, Teja R, **Ho MM**, Puddefoot JR & Hinson JP 1995 Zonation, paracrine function and aldosterone secretion in the rat adrenal cortex. *Endocr.Res.* **21** 1-12.
9. Vinson GP, **Ho MM**, Puddefoot JR, Teja R, Barker S, Kapas S & Hinson JP 1995 The relationship between the adrenal tissue renin-angiotensin system, internalization of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. *Adv.Exp.Med.Biol.* **377** 319-329.
8. Vinson GP, **Ho MM** & Puddefoot JR 1995 The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems. *Mol.Med.Today* **1** 35-39.
7. Vinson GP, **Ho MM**, Puddefoot JR, Teja R, Barker S, Kapas S & Hinson JP 1995 Internalisation of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. *Endocr.Res.* **21** 211-217.
6. **Ho MM**, Barker S & Vinson GP 1994 Distribution of the adrenocortical inner zone antigen. *J.Endocrinol.* **141** 459-466.
5. Kapas S, Hinson JP, Puddefoot JR, **Ho MM** & Vinson GP 1994 Internalization of the type I angiotensin II receptor (AT1) is required for protein kinase C activation but not for inositol trisphosphate release in the angiotensin II stimulated rat adrenal zona glomerulosa cell. *Biochem.Biophys.Res.Commun.* **204** 1292-1298.
4. Vinson GP, **Ho MM**, Puddefoot JR, Teja R & Barker S 1994 Internalisation of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. *J.Endocrinol.* **141** R5-R9.
3. Barker S, Marchant W, **Ho MM**, Puddefoot JR, Hinson JP, Clark AJ & Vinson GP 1993 A monoclonal antibody to a conserved sequence in the extracellular domain recognizes the angiotensin II AT1 receptor in mammalian target tissues. *J.Mol.Endocrinol.* **11** 241-245.
2. **Ho MM** & Vinson GP 1993 11 beta-Hydroxylase gene expression in the rat adrenal cortex. *J.Endocrinol.* **139** 301-306.
1. Barker S, Laird SM, **Ho MM**, Vinson GP & Hinson JP 1992 Characterization of a rat adrenocortical inner zone-specific antigen and identification of its putative precursor. *J.Mol.Endocrinol.* **9** 95-102.